Ensysce Biosciences (ENSC) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Ensysce Biosciences
Is Ensysce Biosciences a buy right now? The alternative data says hold. This ENSC stock analysis is built on the 25+ alternative data signals AltIndex tracks on Ensysce Biosciences every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 44/100: a Hold. The stock trades at $0.42 with a $7M market cap.
The soft spots over the past 90 days: web traffic down 6.3% to 3K monthly visits. The rest of the signal set is holding steady, which keeps ENSC at a hold rather than a sell.
ENSC’s broader alt-data profile also covers headcount (13 employees, according to LinkedIn), X followers (394), Reddit mentions (1 a day), and sentiment (93/100). Every signal links to its own page with full history, the ENSC technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ENSC is just below.
Ensysce Biosciences AI Stock Analysis
1. Company Overview Ensysce Biosciences (NASDAQ: ENSC) is a clinical-stage biotechnology company focused on developing abuse-deterrent and overdose-protection opioid medications. Its core scientific thesis is to use proprietary chemistry to create safer pain therapies that reduce the risk of addiction, misuse, and fatal overdose.
Analysis generated August 7, 2026.
Recent Ensysce Biosciences Stock Alerts
|
Ensysce Biosciences | August 11 Price is up by 10.7% in the last 24h. |
|
Ensysce Biosciences | August 10 Price is down by -11.8% in the last 24h. |
|
Ensysce Biosciences | August 7 Price is down by -6.1% in the last 24h. |
|
Ensysce Biosciences | August 6 Price is up by 81.6% in the last 24h. |
Ensysce Biosciences Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 3K | 6.3% | |
| LinkedIn Employees | 13 | N/A | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 93 | 3.1% | |
| Reddit Mentions | 1 | N/A | |
| X Mentions | 11 | N/A | |
| Stocktwits Mentions | 2K | 421.5% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 10K | 3.3% | |
| X Followers | 394 | 0.8% | |
| Facebook Followers | 32 | 0% | |
| Facebook Engagement | 0 | N/A |
About Ensysce Biosciences (ENSC)
Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. The company is headquartered in La Jolla, California.
| Price | $0.42 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $7M |
| Year Range | $0 – $3 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Ensysce Biosciences News
View more →
Postoperative Pain - Pipeline Insight, 2026 Now Available; Comprehensive Profiles of 40+ Key Players Including Ensysce Biosciences and Allay TherapeuticsJuly 9 - GlobeNewswire |
|
Why Investors Are Watching These Healthcare MoversAugust 6 - GlobeNewswire |
|
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of GrowthJuly 13 - GlobeNewswire |
|
Ensysce Biosciences Earnings & Financial Performance
View all earnings →Ensysce Biosciences Insider Trading Activity
View all →| No recent insider transactions on file. |
Ensysce Biosciences Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Ensysce Biosciences
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Alzamend NeuroALZN |
$1.47 0.7% | $7M | 32 |
 |
Enveric BiosciencesENVB |
$1.55 0.7% | $6M | 40 |
 |
XTL BiopharmaceuticalsXTLB |
$2.65 7.7% | $7M | 44 |
 |
CollPlant BiotechnologiesCLGN |
$0.30 9.2% | $6M | 45 |
 |
Cadrenal TherapeuticsCVKD |
$1.94 0.0% | $6M | 49 |
Explore Ensysce Biosciences Data
Frequently Asked Questions: Ensysce Biosciences (ENSC)
Ensysce Biosciences has an AltIndex AI Score of 44/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
44/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Ensysce Biosciences (ENSC) stock is $0.42 with a market cap of $7M.
As of today, Ensysce Biosciences’s PE (Price to Earnings) ratio is —.
View the latest Ensysce Biosciences insider transactions to see recent buying and selling activity by company executives and directors.
Check the Ensysce Biosciences congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ENSC stock price chart above shows Ensysce Biosciences’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Ensysce Biosciences technical analysis for RSI, moving averages, and more.
See the stocks similar to Ensysce Biosciences section on this page for companies in the same industry ranked by market cap and AI Score.
